Juvelook vs Juvelook Volume

Juvelook and Juvelook Volume are two named PDLLA plus HA presentations, not interchangeable shorthand for the same vial. On VAIM’s Korean product page, Juvelook contains 42.5 mg poly-D,L-lactic acid (PDLLA) plus 7.5 mg hyaluronic acid (HA), while Juvelook Volume contains 170 mg PDLLA plus 30 mg HA. Both pages display the same broad Korean intended-use wording, but shared wording does not establish identical preparation, particle specification, placement, or clinical role.

This page compares the two Korean names. It does not rank them or supply a treatment protocol.

At a glance

Field	Juvelook	Juvelook Volume
Listed composition	42.5 mg PDLLA + 7.5 mg HA (VAIM Korean product information 🔗)	170 mg PDLLA + 30 mg HA (VAIM Korean product information 🔗)
Total listed content	50 mg (VAIM Korean product information 🔗)	200 mg (VAIM Korean product information 🔗)
Relative content per vial	Reference presentation	Four times the listed PDLLA and HA mass of the 50 mg presentation; this arithmetic does not establish dose equivalence after preparation
Company-reported nominal particle context	A 2025 VAIM-hosted interview describes 25 μm (VAIM interview 🔗)	The same interview describes 40 μm (VAIM interview 🔗)
Korean public intended use	Subcutaneous injection of polylactide and HA for temporary improvement of adult facial wrinkles through physical restoration (VAIM Korean product information 🔗)	Same public wording on the current Korean product page (VAIM Korean product information 🔗)
Direct clinical evidence discussed here	Preliminary whole-face study of the 42.5 mg + 7.5 mg presentation (Journal of Cosmetic Dermatology 🔗)	Randomized split-face nasolabial-fold study of the 170 mg + 30 mg presentation (Juvelook Volume study 🔗)

The nominal particle statements are company-reported characterization from a media interview, not a regulator-hosted specification or proof of a clinical advantage. A larger stated particle size should not be translated into a universal placement rule, safety ranking, injectability claim, or outcome prediction.

What the four-fold content difference does—and does not—mean

The Korean product page lists exactly four times as much PDLLA and HA in a Juvelook Volume vial as in a Juvelook vial. That is a mass comparison between supplied presentations. It does not mean that:

• one prepared milliliter contains four times as much material;
• one vial of Volume is clinically equivalent to four vials of Juvelook;
• preparation volume, concentration, particle distribution, or delivery method is interchangeable;
• treatment area or approved placement can be inferred from the word Volume;
• outcome magnitude or duration scales linearly with vial content.

Those questions require the exact IFU or a product-specific study with its preparation and delivery method visible.

The Korean intended-use wording is shared but broad

VAIM presents both products as Class IV medical devices in the Korean soft-tissue repair material (조직수복용재료) category. Its public page uses the same purpose statement for Juvelook and Juvelook Volume: polylactide and HA are injected subcutaneously to temporarily improve adult facial wrinkles through physical restoration (VAIM Korean product information 🔗).

This shared wording is important, but it is not a complete equivalence statement. It does not establish identical preparation, particle-size acceptance criteria, device compatibility, anatomical guidance, package configuration, contraindications, warnings, or adverse-event instructions.

Use the current Korean approval record and presentation-specific IFU for controlling clinical instructions. Company media and published techniques remain separate from the approved purpose.

The product name is not an instruction

Juvelook is not automatically a superficial product, and Juvelook Volume is not automatically authorized for every area where volume is desired. Confirm the exact local label, anatomy, placement, and preparation rather than deriving them from commercial naming.

Published evidence belongs to the named presentation

Juvelook 50 mg

A preliminary whole-face study identified its material as 42.5 mg PDLLA plus 7.5 mg non-cross-linked HA. The investigators used a 10 mL study mixture that included additional HA, lidocaine, and saline and evaluated skin-related outcomes in a small, uncontrolled study (Journal of Cosmetic Dermatology 🔗).

This supports interpretation of that specific study intervention. It does not establish the current Korean IFU, a universal family preparation, or results for the 200 mg Volume presentation.

Juvelook Volume 200 mg

A randomized, evaluator-blinded, split-face study compared Juvelook Volume with a PLLA product for nasolabial folds. The article identifies Juvelook Volume as 170 mg PDLLA plus 30 mg non-cross-linked HA and reports follow-up through 24 weeks (Juvelook Volume split-face study 🔗).

Both sides improved in the study. One participant developed moderate swelling and tenderness after the second Juvelook Volume treatment; the authors attributed it to localized excess HA. The relatively short follow-up, subjective outcome measures, and single studied protocol limit broader safety and durability conclusions.

The study does not show that Volume is better than Juvelook 50 mg because those two products were not directly compared.

Preparation cannot be reconstructed across papers

The supplied dry product, reconstitution liquid, additives, total prepared volume, particle concentration, mixing process, administration tool, and placement all affect what a published intervention represents.

Therefore:

• do not apply the 50 mg study mixture to Juvelook Volume;
• do not divide or multiply a Volume protocol solely from the four-fold vial-content ratio;
• do not treat a study method as Korean approved labeling;
• do not merge instructions for Juvelook i, Skin, G, or overseas names into either product.

The current public product page states composition and intended use but does not provide enough detail to construct a full clinical preparation protocol.

Immediate and delayed interpretation

Both products combine particulate PDLLA with HA. Immediately after administration, prepared fluid, HA, edema, and physical distribution can all affect appearance. Later observations are commonly discussed in relation to tissue response around PDLLA particles.

Keep these phases separate. The HA component does not make the complete hybrid implant equivalent to a conventional HA-only filler, and use of hyaluronidase does not establish removal of PDLLA particles or complete reversal of the whole treatment.

Company and regional identity

VAIM operates the Korean Juvelook product site. Separately, an Italian Ministry of Health safety record names VAIM Co., Ltd. as manufacturer for the Juvelook soft-tissue injectable implant in that notice (Italian Ministry of Health 🔗).

That record supports the manufacturer role for the named device and notice. It does not establish that Juvelook, Juvelook Volume, Lenisna, or other regional names share an identical certificate, label, distributor, or commercial availability. Preserve the market and exact product name when linking evidence.

Practical selection framework

The defensible comparison is not skin quality versus volume as a slogan. It is a document check:

1. exact presentation and listed PDLLA/HA content;
2. current local approval and intended anatomy;
3. presentation-specific IFU and preparation;
4. particle specification from a controlling technical source;
5. evidence matching the treatment objective, placement, and follow-up period;
6. patient-specific risk and ability to manage early or delayed complications.

For the complete family map, see Juvelook. The AestheFill vs Juvelook page explains why a PDLLA + CMC suspension should not be treated as the same system, while PDLLA separates material identity from finished-product design.